Jens‐Michael Seibel

Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells

Steffen Wedel, Lukasz Hudak, Jens‐Michael Seibel et al. · Clinical & Experimental Metastasis · 2011 · 54 citations

Urology, Mtor Inhibition, Cell Adhesion +10

Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001

Steffen Wedel, Lukasz Hudak, Jens‐Michael Seibel et al. · Life Sciences · 2010 · 35 citations

Urology, Oncology, Medicine +9

Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis

Steffen Wedel, Lukasz Hudak, Jens‐Michael Seibel et al. · BMC Cancer · 2011 · 28 citations · Full text

Combined targeting of the VEGFr/EGFr and the mammalian target of rapamycin (mTOR) signaling pathway delays cell cycle progression and alters adhesion behavior of prostate carcinoma cells

Steffen Wedel, Lukasz Hudak, Jens‐Michael Seibel et al. · Cancer Letters · 2010 · 17 citations

Mammalian Target, Signaling Pathway, Prostate Carcinoma Cells +7

Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer

Steffen Wedel, Lukasz Hudak, Jens‐Michael Seibel et al. · The Prostate · 2010 · 12 citations